Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Grace is a clinical-stage, biotechnology company focused on rare disease.</li><li>Its lead program, GTx-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).</li><li>Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia.</li></ul>

Grace is a clinical-stage, biotechnology company focused on rare disease.Its lead program, GTx-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia.

<ul><li>Grace is a clinical-stage, biotechnology company focused on rare disease.</li><li>Its lead program, GTX-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).</li><li>Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia.</li></ul>

Grace is a clinical-stage, biotechnology company focused on rare disease.Its lead program, GTX-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH).Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia.

United States

Grace Therapeutics, Inc. operates as a late-stage biopharma company. The Company focuses on drug delivery and technologies addressing rare and orphan diseases. Grace Therapeutics serves clients in Canada and the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Grace Therapeutics (GRCE US)

GRCE: Looking Ahead to Acceptance

Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTx-104, is a novel injectable formulation of...

Zacks Small Cap Research

GRCE: NDA Submitted

Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTx-104, is a novel injectable formulation of...

Zacks Small Cap Research

GRCE: Progress Report

Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTx-104, is a novel injectable formulation of...

Zacks Small Cap Research

GRCE: STRIVE-ON Results Reported

Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTX-104, is a novel injectable formulation of...

Zacks Small Cap Research

GRCE: aSAH KOL Summary

Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTX-104, is a novel injectable formulation of...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)